What are the basic pharmacology definitions, including pharmacodynamics, pharmacokinetics, agonist, antagonist, partial agonist, therapeutic index, bioavailability, half‑life, clearance, volume of distribution, enzyme induction and inhibition, drug interactions, adverse drug reactions, tolerance, and dependence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Basic Pharmacology Definitions

Pharmacology is fundamentally divided into two core disciplines: pharmacokinetics (what the body does to a drug) and pharmacodynamics (what the drug does to the body), with understanding both being essential for safe and effective medication use. 1

Core Pharmacological Disciplines

Pharmacokinetics

Pharmacokinetics encompasses four fundamental processes that determine drug concentration over time 1:

  • Absorption: How the drug enters the bloodstream
  • Distribution: How the drug spreads throughout body tissues and fluids
  • Metabolism: How the drug is chemically transformed (primarily by hepatic enzymes)
  • Excretion: How the drug and its metabolites are eliminated from the body

Pharmacodynamics

Pharmacodynamics describes the biochemical and physiological effects of drugs on the body, typically through interaction with specific receptor sites. 2 This includes:

  • The mechanism of drug action at molecular, cellular, and organ system levels
  • The relationship between drug concentration and effect
  • Time course of therapeutic and adverse effects

Drug-Receptor Interactions

Agonist

A ligand that binds to a receptor and initiates a chain of reactions leading to a pharmacological response 2. Agonists possess both affinity (ability to bind) and efficacy (ability to produce an effect).

Antagonist

A drug that binds to receptors but fails to initiate the transduction pathways, thereby competing with agonists for receptor occupancy and inhibiting their actions 2. Antagonists have affinity but lack efficacy.

Partial Agonist

A drug that binds to receptors and produces a submaximal response even when occupying all available receptors, possessing intermediate efficacy between full agonists and antagonists 2.

Key Pharmacokinetic Parameters

Bioavailability

The fraction of administered drug that reaches systemic circulation unchanged 1. Route of administration dramatically affects bioavailability—intravenous administration provides 100% bioavailability, while oral administration may be significantly lower due to first-pass metabolism 3.

Half-Life (t½)

The time required for plasma drug concentration to decrease by 50% 4, 1. This parameter determines dosing frequency and time to steady state (typically achieved after 4-5 half-lives).

Volume of Distribution

A theoretical volume that relates the amount of drug in the body to plasma concentration 1. Large volumes suggest extensive tissue distribution; small volumes indicate the drug remains primarily in plasma.

Clearance

The volume of plasma from which drug is completely removed per unit time 1. This is the most important parameter for determining maintenance dosing requirements and reflects the body's ability to eliminate the drug.

Drug Metabolism Concepts

Enzyme Induction

A process where certain drugs increase the expression and activity of metabolic enzymes (particularly cytochrome P450 enzymes), leading to decreased plasma concentrations of drugs metabolized by those enzymes 5. This is a slower process, typically requiring 7-10 days to manifest 6.

Critical pitfall: Enzyme induction can cause therapeutic failure of co-administered drugs, particularly those with narrow therapeutic windows. CYP3A4 is responsible for metabolizing over 50% of all marketed drugs 5.

Enzyme Inhibition

The blocking of metabolic enzyme activity, resulting in increased plasma concentrations and potential toxicity of drugs metabolized by those enzymes 5. This occurs rapidly, typically within 24-48 hours 6.

Critical pitfall: For drugs where the parent compound is more active than metabolites, enzyme inhibition increases both therapeutic and toxic effects. Conversely, for prodrugs, inhibition may decrease therapeutic efficacy 5.

Drug Interactions

Pharmacokinetic Drug Interactions

Occur when one drug alters the absorption, distribution, metabolism, or excretion of another drug, resulting in changed plasma concentrations 4, 6. These interactions can be mediated through:

  • Drug-metabolizing enzymes
  • Drug transporters
  • Orphan nuclear receptors regulating enzyme/transporter expression 6

Pharmacodynamic Drug Interactions

Occur when one drug modifies the pharmacological effect of another in an additive, synergistic, or antagonistic fashion without altering plasma drug levels 4, 7. These involve drugs acting on the same or related receptor systems.

Important consideration: While pharmacokinetic interactions are generally negligible for drugs with wide therapeutic windows, serious clinical consequences can occur from small changes in drugs with narrow therapeutic indices, particularly anticancer agents 5.

Safety Parameters

Therapeutic Index

The ratio between the dose that produces toxicity and the dose that produces therapeutic effect. A narrow therapeutic index indicates small differences between effective and toxic doses, requiring careful monitoring.

Adverse Drug Reactions

Unintended, harmful responses to medications occurring at doses normally used for treatment. These must be distinguished from drug-drug interactions, though medication-related issues are often reported as adverse reactions rather than interactions 4.

Tolerance

A state where repeated drug administration results in diminished pharmacological effect, requiring dose escalation to maintain the same response. This often develops with drugs having long half-lives and sufficient exposure duration 3.

Dependence

A physiological state where drug discontinuation produces withdrawal symptoms (negative reinforcement), which becomes a major driver for recurrent use 3. This is distinct from tolerance but often coexists.

Clinical Application Principles

The clinical significance of any pharmacological interaction depends on both medication-specific factors (binding affinity, half-life, dose, timing) and patient-specific factors (age, sex, genetic polymorphisms, hepatic/renal function) 4. Approximately 2.8% of hospital admissions result directly from drug-drug interactions, though this likely underestimates true incidence 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.